Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Encourages Close Look At Safety Of Emphysema Device

Executive Summary

The safety risks of an implanted device used to treat hyperinflated lungs associated with severe emphysema will be discussed at a June 14 FDA panel meeting on a PMA submission for the device from BTG.

Advertisement

Related Content

FDA Panel: Benefits Unproven For BTG Emphysema Treatment
Market Intel: Promising Data At ATS2018 Inflate Hopes For Endobronchial Valves And New Device-Based COPD Therapies
BTG Heads To Panel Next Month For Emphysema Device

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel